She has spent her career investigating some of the world's most pervasive infectious diseases—HIV and Ebola, just to name a couple—and now Hanneke Schuitemaker, Ph.D., is fighting a virus that could very well define her career.
This Thursday, we will host Day 1 of the Porter Novelli Purpose Summit: Committing to Action Amid COVID‐19, which will take an in-depth look at how the pandemic is accelerating the transformation of business as a force for good.
Over the past few weeks, I’ve heard from nurses and leaders of national nurses organizations about the critical challenges nurses and other health workers on the frontlines of COVID-19 are facing, such as a dwindling inventory of PPE, a need for proper PPE training, concerns over nurse burnout and uncertainty about the nature of this virus.
Alexion partners with a wide variety of third parties to deliver the goods and services required to support the discovery, development and commercialization of life-changing therapies.
The coronavirus pandemic is changing daily life as we know it. Society at large is grappling with how we live and work during a time when the only certainty is more uncertainty.
This week in Episode 3, Lisa Ling interviews National Academies member and University of Connecticut professor Cato Laurencin, M.D., Ph.D., to learn what his new coronavirus study reveals. Plus, what’s needed to mass-produce a vaccine.
This week, Lisa Ling speaks with three leading scientists who have been on the frontlines of Zika, malaria and HIV to give you the inside scoop on the latest in the development of a coronavirus vaccine, and the process of going from lab to clinic.
The Verizon Foundation serves as an incubator for exploring how our technical and human resources can be applied in new ways to the practical concerns...
Diverse teams build better products — period. At GoDaddy, we make apps and services that our worldwide community of entrepreneurs can relate to. Our...
